- Home
- GOVX vs BLRX Comparison
GOVX vs BLRX Comparison
Compare GOVX & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- BLRX
- Stock Information
- Founded
- GOVX 2001
- BLRX 2003
- Country
- GOVX United States
- BLRX Israel
- Employees
- GOVX N/A
- BLRX N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- GOVX Health Care
- BLRX Health Care
- Exchange
- GOVX Nasdaq
- BLRX Nasdaq
- Market Cap
- GOVX 15.5M
- BLRX 15.3M
- IPO Year
- GOVX N/A
- BLRX 2011
- Fundamental
- Price
- GOVX $0.95
- BLRX $4.45
- Analyst Decision
- GOVX Strong Buy
- BLRX Strong Buy
- Analyst Count
- GOVX 5
- BLRX 2
- Target Price
- GOVX $12.40
- BLRX $19.00
- AVG Volume (30 Days)
- GOVX 1.5M
- BLRX 2.1M
- Earning Date
- GOVX 08-05-2025
- BLRX 08-14-2025
- Dividend Yield
- GOVX N/A
- BLRX N/A
- EPS Growth
- GOVX N/A
- BLRX N/A
- EPS
- GOVX N/A
- BLRX N/A
- Revenue
- GOVX $5,591,576.00
- BLRX $22,340,000.00
- Revenue This Year
- GOVX N/A
- BLRX N/A
- Revenue Next Year
- GOVX N/A
- BLRX N/A
- P/E Ratio
- GOVX N/A
- BLRX N/A
- Revenue Growth
- GOVX N/A
- BLRX 91.68
- 52 Week Low
- GOVX $0.73
- BLRX $2.30
- 52 Week High
- GOVX $11.18
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- GOVX 46.22
- BLRX 50.17
- Support Level
- GOVX $0.85
- BLRX $3.79
- Resistance Level
- GOVX $1.39
- BLRX $4.62
- Average True Range (ATR)
- GOVX 0.15
- BLRX 0.56
- MACD
- GOVX -0.02
- BLRX -0.13
- Stochastic Oscillator
- GOVX 18.52
- BLRX 21.79
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.